Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kylo-02
- Development stage
- Preclinical
- Lead developer
- Kylonova Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Kylo-02 is an investigational siRNA therapeutic developed by Kylonova for the treatment of Chronic Hepatitis B (CHB). The drug consists of siRNA molecules targeting the Hepatitis B surface antigen (HBsAg) and Hepatitis B e antigen (HBeAg), which are critical for viral replication and immune evasion. These siRNA molecules are encapsulated in Kylonova's proprietary Nano-lipid Particles Delivery Platform (NPDP) to facilitate delivery to the liver. The mechanism of action involves the degradation of viral mRNA, thereby interrupting the HBV replication cycle and reducing the production of viral particles. Kylo-02 is designed for use in combination with nucleoside/nucleotide analogues (NUCs) and interferon to potentially achieve a functional cure for CHB. It is currently in the IND-enabling stage of development.
02
Targets
HBeAg (Hepatitis B e antigen)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Kylo-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kylo-02.